Literature DB >> 3880780

The effects of terodiline and meladrazine on severe motor urge incontinence in geriatric patients.

H O Beisland, E Fossberg.   

Abstract

Twenty-five geriatric patients with severe motor urge incontinence were treated with terodiline and meladrazine separately and in combination. Because of poor general state of health and serious concomitant diseases the frequency of dropouts was high. Separate administration of the drugs improved the majority of the patients subjectively, but not sufficient for complete continence. Urodynamically, however, significant improvement was found only with terodiline. On combined administration with both drugs, seven of 15 patients became completely continent, seven were improved, and one remained unchanged, but additional urodynamic improvement was not demonstrated. Meladrazine caused a high incidence of side effects; therefore, treatment with terodiline separately is recommended for geriatric patients who have severe motor urge incontinence.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880780     DOI: 10.1111/j.1532-5415.1985.tb02856.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  4 in total

1.  Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.

Authors:  B Hallén; A Magnusson; S Bogentoft; P Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 3.  Anticholinergic drugs versus other medications for overactive bladder syndrome in adults.

Authors:  C Roxburgh; J Cook; N Dublin
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

4.  Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.

Authors:  B Hallén; S Bogentoft; S Sandquist; S Strömberg; G Setterberg; E Ryd-Kjellén
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.